Last reviewed · How we verify
Rybrevant (AMIVANTAMAB)
Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells.
At a glance
| Generic name | AMIVANTAMAB |
|---|---|
| Sponsor | Johnson & Johnson |
| Target | EGFR, MET |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2021 |
| Annual revenue | 800 |
Mechanism of action
Amivantamab-vmjw is a bispecific antibody that binds to EGFR and MET receptors on tumor cells. By blocking ligand binding or degrading these receptors, it disrupts their signaling functions, which can drive tumor growth. Additionally, it enhances the ability of immune cells like natural killer cells and macrophages to destroy tumor cells through ADCC and trogocytosis.
Approved indications
- Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Common side effects
- Rash
- Infusion related reaction
- Paronychia
- Musculoskeletal pain
- Dyspnea
- Nausea
- Fatigue
- Edema
- Stomatitis
- Cough
- Constipation
- Vomiting
Key clinical trials
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (PHASE2)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PHASE3)
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1,PHASE2)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rybrevant CI brief — competitive landscape report
- Rybrevant updates RSS · CI watch RSS
- Johnson & Johnson portfolio CI